Skip to main
CERT

Certara (CERT) Stock Forecast & Price Target

Certara (CERT) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

Certara Inc demonstrates a strong growth trajectory through its innovative biosimulation software and technology, which is advancing the drug discovery and development process, thereby enhancing client efficiency and market access. The company's strategic positioning in key regions, particularly in the Americas, indicates a robust revenue-generating potential amid increasing demand for its modeling, simulation, and regulatory science services. Furthermore, Certara's ability to capitalize on the ongoing improvements in its production profile aligns well with the overall upward trends in the healthcare market, supporting a positive outlook for the firm.

Bears say

Certara Inc. faces a negative outlook primarily due to declining production levels linked to lower-grade stockpiles impacting operational efficiency. Additionally, the assigned fixed value of $22.0 million for the Mont Sorcier Project appears overly conservative compared to its previously reported $1.6 billion net present value from the 2022 feasibility study, suggesting that future revenue generation might be hindered. Furthermore, despite a reduction in the corporate income tax rate potentially attracting investments, there are growing concerns regarding the company's ability to capitalize on market opportunities amid operational setbacks.

Certara (CERT) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Certara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Certara (CERT) Forecast

Analysts have given Certara (CERT) a Buy based on their latest research and market trends.

According to 8 analysts, Certara (CERT) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Certara (CERT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.